Table 2.

Risk of non-persistence of biosimilar use versus originator use in infliximab-initiating patients, by pathology

Pathology	Reference events	Biosimilars events	Crude HR	P value	IPTW aHR	P value
Rheumatoid arthritis	48% (228/472)	51% (798/1570)	0.95 (0.78 to 1.16)	0.534	0.88 (0.63 to 1.23)	0.300
Ankylosing spondylitis	41% (330/806)	43% (1407/3253)	0.98 (0.84 to 1.16)	0.797	0.84 (0.67 to 1.07)	0.057
Psoriasic arthritis	39% (61/155)	44% (199/456)	1.08 (0.74 to 1.60)	0.580	0.87 (0.45 to 1.69)	0.590
Crohn’s disease	35% (829/2369)	32% (2272/7162)	0.85 (0.77 to 0.95)	<0.001	0.83 (0.71 to 0.96)	<0.001
Ulcerative colitis	38% (394/1044)	41% (1626/4010)	1.05 (0.91 to 1.22)	0.375	0.90 (0.74 to 1.11)	0.193
Psoriasis	41% (184/446)	50% (459/927)	1.28 (1.02 to 1.61)	0.005	0.98 (0.70 to 1.36)	0.845

HR are presented in point estimates (CI); bold font denotes significant differences. Bonferroni-corrected p value=0.00833.

IPTW computed through a multivariable logistic regression.

aHR, adjusted HR; IPTW, inverse probability of treatment weighting.